MaxCyte, Inc. Proposed Dual-Listing on Nasdaq (6562Y)
May 14 2021 - 2:00AM
UK Regulatory
TIDMMXCT TIDMTTM
RNS Number : 6562Y
MaxCyte, Inc.
14 May 2021
Proposed Dual-Listing on Nasdaq
This announcement contains inside information
Gaithersburg, Maryland - May 14, 2021 - MaxCyte, Inc. (LSE:
MXCT, MXCL, MXCN) ("MaxCyte" or the "Company"), a leading provider
of platform technologies for cell engineering, today announces that
it has confidentially submitted a draft registration statement on
Form S-1 with the Securities and Exchange Commission (the "SEC")
relating to a proposed dual-listing and public offering of shares
of common stock on the Nasdaq Stock Market (the "Offering").
The number of securities to be offered and the price for the
proposed Offering have not yet been determined. The Offering is
expected to commence after the SEC completes its review process,
subject to market and other conditions, and shareholders and
potential investors should note that the proposed Offering may or
may not proceed.
This press release is being made pursuant to, and in accordance
with, Rule 135 under the Securities Act of 1933, as amended (the
"Securities Act"). This press release does not constitute an offer
to sell or the solicitation of an offer to buy securities, and
shall not constitute an offer, solicitation or sale in any
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of that jurisdiction. Any offers, solicitations or
offers to buy, or any sales of securities will be made in
accordance with the registration requirements of the Securities
Act.
About MaxCyte
MaxCyte is a leading commercial cell-engineering company focused
on providing enabling platform technologies to advance innovative
cell-based research as well as next-generation cell therapeutic
discovery, development and commercialization. MaxCyte's existing
customer base ranges from large biopharmaceutical companies,
including all of the top 10, and 20 of the top 25, pharmaceutical
companies based on 2020 global revenue, to hundreds of
biotechnology companies and academic centers focused on
translational research. MaxCyte has granted 12 strategic platform
licences to commercial cell therapy developers. Including these
strategic platform licences, MaxCyte has granted research and
clinical licences with academic and industry customers covering
over an estimated 140 programs, and clinical licences with academic
and industry customers covering over an estimated 100 programs
being developed for use in humans. MaxCyte was founded in 1998 and
is headquartered in Gaithersburg, Maryland, US.
###
For further information, please contact:
MaxCyte Inc. +1 301-944-1660
Doug Doerfler, Chief Executive Officer
Amanda Murphy, Chief Financial Officer
Nominated Adviser and Joint Corporate
Broker
Panmure Gordon +44 (0)20 7886 2500
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden
Joint Corporate Broker
Numis Securities Limited +44 (0)20 7260 1000
James Black / Duncan Monteith / Matthew
O'Dowd
Financial PR Adviser
Consilium Strategic Communications +44 (0)203 709 5700
Mary-Jane Elliott / Chris Welsh maxcyte@consilium-comms.com
US Media Adviser
Jamie Lacey-Moreira +1 410-299-3310
jamielacey@presscommpr.com
The person responsible for arranging the release of this
announcement on behalf of the Company is Doug Doerfler, President
and Chief Executive Officer of MaxCyte, Inc.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCFIFEEEIISLIL
(END) Dow Jones Newswires
May 14, 2021 02:00 ET (06:00 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jul 2023 to Jul 2024